Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BGISEQ-500 Cancer Dataset - WGS tumour/normal pairs

ABSTRACT: This study contains whole genome sequencing data for 3 matched tumour / normal pairs from Mesothelioma patients. The sequencing is 50bp paired-end generated using the BGISEQ-500 and is provided as 6 aligned and duplicate-marked BAM files.

PROVIDER: EGAS00001002298 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

BGISEQ-500 WGS

Project description:The performance of BGISEQ-500 for whole genome sequencing.

| PRJEB19427 | ENA

Mesothelioma Genomics Study - WGS tumour/normal pairs

Project description:Malignant mesothelioma (MM) is an incurable and aggressive tumour that occurs principally in the pleura as a consequence of inhaling asbestos fibres. There are >15,000 cases per annum worldwide, the incidence is increasing and Australia has one of the world's highest incidence rates. Surgery, chemotherapy and radiotherapy (or their combinations) all feature in the clinical management but do not impact significantly on overall survival. This study uses whole genome sequencing (WGS) with the aim of identifying mesothelioma-related genomic alterations and potentially identifying novel treatment strategies.

| EGAS00001002299 | EGA

BGISEQ-500 WGS demo FASTQ data

Project description:BGISEQ-500 WGS demo FASTQ data

| PRJEB15427 | ENA

MWAS_BGISEQ-500

Project description:Assessment of the cPAS-based BGISEQ-500 platform for metagenomic sequencing

| PRJEB35961 | ENA

BGISEQ-500 WES

Project description:The performance of BGISEQ-500 for whole exome sequencing

| PRJEB19426 | ENA

BGISEQ-500 RNA-Seq

Project description:The performance of BGISEQ-500 for RNA-Seq

| PRJEB19428 | ENA

Gene expression changes between primary mesothelioma tumour cells and commercially available cell lines, compared to normal primary mesothelial cells

Project description:Malignant mesothelioma (MM) is an aggressive, fatal tumour strongly associated with asbestos exposure. There is an urgent need to improve MM patient outcomes and this requires functionally validated pre-clinical models. Mesothelioma-derived cell lines provide an essential and robust tool widely used for candidate drug evaluation. Although a number of cell lines are commercially available, a detailed comparison of these lines with freshly-derived primary tumour cells to validate their suitability as pre-clinical models is lacking. Patient-derived primary mesothelioma cell lines were established and characterised by gene expression profiling. Molecular profiling revealed a significantly different transcriptome in commercially available compared with primary cell lines. Primary mesothelioma cell lines are more representative of the tumour close to its native state and show a degree of molecular diversity, thus capturing the disease heterogeneity in a patient cohort.

2018-02-01 | E-MTAB-6351 | biostudies-arrayexpress

BGISEQ-500 RNA-seq demo FASTQ data

Project description:BGISEQ-500 RNA-seq demo FASTQ data

| PRJEB15426 | ENA

BGISEQ-500 ChIP-Seq SE50 demo data

Project description:BGISEQ-500 ChIP-Seq SE50 demo data

| PRJEB20179 | ENA

Hiseq 2500 vs BGISeq-500

Project description:Comparative performance of the BGISEQ-500 vs Illumina sequencing platforms for palaeogenomic sequencing

| PRJEB21089 | ENA